Scribe Therapeutics Files to Raise IPO Funds for CRISPR Pipeline

Scribe Therapeutics Inc. filed an S-1 registration statement for an initial public offering, the company said. The clinical-stage biotech develops CRISPR-based gene editing therapies. Its lead candidate targets a neurodegenerative disease, though the filing did not name the specific indication.

The IPO will fund preclinical and early-stage clinical work. Scribe has not yet set a price range or number of shares. The offering is expected to trade on the Nasdaq under the ticker SCTX.

IPO proceeds for a pre-revenue biotech carry execution risk. Gene editing platforms face regulatory scrutiny on off-target effects and long-term safety. Scribe’s pipeline is early; no candidate has entered Phase 2 trials. The S-1 lists cash burn and reliance on future financing as key risk factors.

Underwriters for the offering were not disclosed in the initial filing.